{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:11:18Z","timestamp":1716498678266},"reference-count":31,"publisher":"Medical Journals Sweden AB","issue":"11","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v101.439","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T13:42:44Z","timestamp":1635169364000},"page":"adv00600","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan"],"prefix":"10.2340","volume":"101","author":[{"given":"Ryoko","family":"Kimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"8480","unstructured":"Eriksson C, Gustavsson A, Kronvall T, Tysk C. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis 2011; 20: 77-80."},{"key":"8481","doi-asserted-by":"crossref","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"8482","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0895-4356(93)90101-6","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"8483","doi-asserted-by":"crossref","unstructured":"Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 2013; 65: 1460-1471.","DOI":"10.1002\/acr.22018"},{"key":"8484","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/acr.22018","DOI":"10.1002\/acr.22018"},{"key":"8485","doi-asserted-by":"crossref","unstructured":"Echizen H. The First-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016; 55: 409-418.","DOI":"10.1007\/s40262-015-0326-7"},{"key":"8486","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40262-015-0326-7","DOI":"10.1007\/s40262-015-0326-7"},{"key":"8487","doi-asserted-by":"crossref","unstructured":"Hersz\u00e9nyi L, Bakucz T, Barab\u00e1s L, Tulassay Z. Pharmacological approach to gastric acid suppression: past, present, and future. Dig Dis 2020; 38: 104-111.","DOI":"10.1159\/000505204"},{"key":"8488","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000505204","DOI":"10.1159\/000505204"},{"key":"8489","doi-asserted-by":"crossref","unstructured":"Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 2019; 35: 344-355.","DOI":"10.1097\/MOG.0000000000000543"},{"key":"8490","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MOG.0000000000000543","DOI":"10.1097\/MOG.0000000000000543"},{"key":"8491","doi-asserted-by":"crossref","unstructured":"Srinivas NR. Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: physiological role of enzymes and transporters. Gen Physiol Biophys 2016; 35: 243-258.","DOI":"10.4149\/gpb_2015050"},{"key":"8492","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4149\/gpb_2015050","DOI":"10.4149\/gpb_2015050"},{"key":"8493","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang C, Wang S, Zhou Q, Dai D, Shi J, et al. Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo. Front Pharmacol 2020; 11: 53.","DOI":"10.3389\/fphar.2020.00053"},{"key":"8494","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2020.00053","DOI":"10.3389\/fphar.2020.00053"},{"key":"8495","doi-asserted-by":"crossref","unstructured":"Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-167.","DOI":"10.2133\/dmpk.20.153"},{"key":"8496","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2133\/dmpk.20.153","DOI":"10.2133\/dmpk.20.153"},{"key":"8497","doi-asserted-by":"crossref","unstructured":"Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos 2012; 40: 1698-1711.","DOI":"10.1124\/dmd.112.045575"},{"key":"8498","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1124\/dmd.112.045575","DOI":"10.1124\/dmd.112.045575"},{"key":"8499","doi-asserted-by":"crossref","unstructured":"Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011; 39: 2020-2033.","DOI":"10.1124\/dmd.111.041293"},{"key":"8500","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1124\/dmd.111.041293","DOI":"10.1124\/dmd.111.041293"},{"key":"8501","doi-asserted-by":"crossref","unstructured":"Li X-Q, Andersson TB, Ahlstr\u00f6m M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827.","DOI":"10.1124\/dmd.32.8.821"},{"key":"8502","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1124\/dmd.32.8.821","DOI":"10.1124\/dmd.32.8.821"},{"key":"8503","doi-asserted-by":"crossref","unstructured":"Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol 2019; 85: 1454-1463.","DOI":"10.1111\/bcp.13914"},{"key":"8504","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bcp.13914","DOI":"10.1111\/bcp.13914"},{"key":"8505","doi-asserted-by":"crossref","unstructured":"Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil 2018; 24: 334-344.","DOI":"10.5056\/jnm18029"},{"key":"8506","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5056\/jnm18029","DOI":"10.5056\/jnm18029"},{"key":"8507","doi-asserted-by":"crossref","unstructured":"Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43: 240-251.","DOI":"10.1111\/apt.13461"},{"key":"8508","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/apt.13461","DOI":"10.1111\/apt.13461"},{"key":"8509","doi-asserted-by":"crossref","unstructured":"Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003; 18: 48-70.","DOI":"10.2133\/dmpk.18.48"},{"key":"8510","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2133\/dmpk.18.48","DOI":"10.2133\/dmpk.18.48"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/439\/1040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/439\/1041","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/439\/1040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T09:20:37Z","timestamp":1675761637000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.2340\/actadv.v101.439","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}